REIGO Investments

Company Overview

Snapshot

Founded in June 2018 by Yariv Omer, Itay Goren, and Uri Zror, REIGO Investments operates with 11–50 employees. The company has raised $13 million across one funding round from Caesarea Medical Holdings. In March 2022, REIGO Investments secured its Series A funding.

Business overview

REIGO Investments operates a real estate investment platform focused on originating and managing hard money loans for first-charge senior positions in the US market. The company leverages data science, artificial intelligence, and machine learning to enhance performance, mitigate default risks, improve portfolio diversification, and streamline the underwriting process. Serving the fintech and real estate sectors, REIGO's technology is designed for B2B applications, targeting financial services and real estate development industries.

Strategic signal

In March 2022, REIGO Investments successfully raised $13 million in Series A funding. This capital injection validates the company's data science-driven approach to real estate debt and signals investor confidence in its model for improving performance and reducing risk in the US real estate lending market. For investors, this indicates a strong growth trajectory and potential for market expansion in a specialized fintech niche.

Company Intelligence Q&A

When was REIGO Investments founded?

REIGO Investments was founded in June 2018.

Who are the founders of REIGO Investments?

The co-founders of REIGO Investments are Yariv Omer, Itay Goren, and Uri Zror.

What is REIGO Investments' primary focus?

REIGO Investments focuses on real estate investments, specifically lending hard money for first-charge senior loans in the US market, utilizing data science to optimize performance and reduce risk.

How much capital has REIGO Investments raised to date?

REIGO Investments has raised a total of $13 million across one funding round.

When did REIGO Investments secure its Series A funding?

REIGO Investments secured its Series A funding in March 2022, raising $13 million from Caesarea Medical Holdings.